ALXN
Income statement / Annual
Last year (2020), Alexion Pharmaceuticals, Inc.'s total revenue was $6.07 B,
an increase of 21.61% from the previous year.
In 2020, Alexion Pharmaceuticals, Inc.'s net income was $603.40 M.
See Alexion Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$6.07 B |
$4.99 B |
$4.13 B |
$3.55 B |
$3.08 B |
$2.60 B |
$2.23 B |
$1.55 B |
$1.13 B |
$783.43 M |
| Cost of Revenue |
$553.50 M
|
$394.50 M
|
$374.30 M
|
$454.20 M
|
$258.00 M
|
$233.09 M
|
$173.86 M
|
$177.56 M
|
$72.84 M
|
$93.14 M
|
| Gross Profit |
$5.52 B
|
$4.60 B
|
$3.76 B
|
$3.10 B
|
$2.83 B
|
$2.37 B
|
$2.06 B
|
$1.37 B
|
$1.06 B
|
$690.29 M
|
| Gross Profit Ratio |
0.91
|
0.92
|
0.91
|
0.87
|
0.92
|
0.91
|
0.92
|
0.89
|
0.94
|
0.88
|
| Research and Development Expenses |
$1.00 B
|
$886.00 M
|
$730.40 M
|
$878.40 M
|
$757.00 M
|
$709.47 M
|
$513.78 M
|
$317.09 M
|
$222.73 M
|
$137.42 M
|
| General & Administrative Expenses |
$1.40 B
|
$1.26 B
|
$1.11 B
|
$1.09 B
|
$954.00 M
|
$862.60 M
|
$630.21 M
|
$489.72 M
|
$384.68 M
|
$308.18 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.40 B
|
$1.26 B
|
$1.11 B
|
$1.09 B
|
$954.00 M
|
$862.60 M
|
$630.21 M
|
$489.72 M
|
$384.68 M
|
$308.18 M
|
| Other Expenses |
$253.70 M
|
$309.60 M
|
$320.10 M
|
$320.10 M
|
$322.00 M
|
$116.58 M
|
$0.00
|
$417,000.00
|
$417,000.00
|
$382,000.00
|
| Operating Expenses |
$2.66 B
|
$2.46 B
|
$2.16 B
|
$2.29 B
|
$2.03 B
|
$1.69 B
|
$1.14 B
|
$807.23 M
|
$607.83 M
|
$445.98 M
|
| Cost And Expenses |
$3.21 B
|
$2.85 B
|
$2.54 B
|
$2.75 B
|
$2.29 B
|
$1.92 B
|
$1.32 B
|
$984.79 M
|
$680.66 M
|
$539.12 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$104.70 M
|
$77.80 M
|
$98.20 M
|
$98.40 M
|
$97.00 M
|
$47.74 M
|
$2.98 M
|
$4.11 M
|
$7.40 M
|
$788,000.00
|
| Depreciation & Amortization |
$329.40 M
|
$376.80 M
|
$405.30 M
|
$496.70 M
|
$396.00 M
|
$166.62 M
|
$46.94 M
|
$28.69 M
|
$23.89 M
|
$17.62 M
|
| EBITDA |
$1.00 B |
$2.63 B |
$745.70 M |
$1.14 B |
$1.07 B |
$712.51 M |
$922.03 M |
$559.07 M |
$428.86 M |
$248.07 M |
| EBITDA Ratio |
0.17
|
0.53
|
0.18
|
0.32
|
0.35
|
0.27
|
0.41
|
0.36
|
0.38
|
0.32
|
| Operating Income Ratio |
0.47
|
0.43
|
0.39
|
0.23
|
0.26
|
0.26
|
0.41
|
0.37
|
0.4
|
0.31
|
| Total Other Income/Expenses Net |
-$2.29 B
|
$38.90 M
|
-$1.35 B
|
-$256.20 M
|
-$217.00 M
|
-$184.17 M
|
-$43.77 M
|
-$40.29 M
|
-$55.88 M
|
-$14.64 M
|
| Income Before Tax |
$569.00 M
|
$2.18 B
|
$242.20 M
|
$547.80 M
|
$576.00 M
|
$498.14 M
|
$872.11 M
|
$526.27 M
|
$397.57 M
|
$229.67 M
|
| Income Before Tax Ratio |
0.09
|
0.44
|
0.06
|
0.15
|
0.19
|
0.19
|
0.39
|
0.34
|
0.35
|
0.29
|
| Income Tax Expense |
-$34.40 M
|
-$225.50 M
|
$164.60 M
|
$104.50 M
|
$177.00 M
|
$353.76 M
|
$215.20 M
|
$273.37 M
|
$142.74 M
|
$54.35 M
|
| Net Income |
$603.40 M
|
$2.40 B
|
$77.60 M
|
$443.30 M
|
$399.00 M
|
$144.39 M
|
$656.91 M
|
$252.90 M
|
$254.82 M
|
$175.32 M
|
| Net Income Ratio |
0.1
|
0.48
|
0.02
|
0.12
|
0.13
|
0.06
|
0.29
|
0.16
|
0.22
|
0.22
|
| EPS |
2.75 |
10.7 |
0.35 |
1.98 |
1.78 |
0.68 |
3.32 |
1.29 |
1.34 |
0.96 |
| EPS Diluted |
2.75 |
10.7 |
0.35 |
1.97 |
1.76 |
0.67 |
3.26 |
1.27 |
1.28 |
0.91 |
| Weighted Average Shares Out |
$219.10 M
|
$224.80 M
|
$224.50 M
|
$223.90 M
|
$224.00 M
|
$213.43 M
|
$198.10 M
|
$195.53 M
|
$190.46 M
|
$183.22 M
|
| Weighted Average Shares Out Diluted |
$219.10 M
|
$224.80 M
|
$224.50 M
|
$225.40 M
|
$227.00 M
|
$215.93 M
|
$201.62 M
|
$199.71 M
|
$198.50 M
|
$191.81 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
